Sélectionner la langue
CCR5
CCR5 Informations sur la molécule
| Nom anglais | C-C chemokine receptor type 5 | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 13 | Alias de la cible | CCR-5，Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene)，C-C Motif Chemokine Receptor 5 A159A，Chemokine Recptor CCR5 Delta32，C-C Chemokine Receptor Type 5，Chemokine Receptor CCR5，CD195 Antigen，C-C CKR-5，CCCKR5，IDDM22，CKR-5，CKR5，Receptors， CCR5，C-C Motif Chemokine Receptor 5，CD195，CHEMR13，CCR5，HIV-1 fusion coreceptor，C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)，Chemokine (C-C Motif) Receptor 5，CC-CKR-5，CMKBR5 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | C-C chemokine receptor type 5 |
| Alias de la cible | CCR-5，Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene)，C-C Motif Chemokine Receptor 5 A159A，Chemokine Recptor CCR5 Delta32，C-C Chemokine Receptor Type 5，Chemokine Receptor CCR5，CD195 Antigen，C-C CKR-5，CCCKR5，IDDM22，CKR-5，CKR5，Receptors， CCR5，C-C Motif Chemokine Receptor 5，CD195，CHEMR13，CCR5，HIV-1 fusion coreceptor，C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)，Chemokine (C-C Motif) Receptor 5，CC-CKR-5，CMKBR5 |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 13 |
| Phase de R&D la plus avancée | Approved |
CCR5 Liste de produits
- Attribut
Protein (4)Cell (1)
- Bibliothèque de produits
En ligne (5)
- Espèces
Human (4)Mouse (1)
- Étiquette
His Tag & Flag Tag (2)- (2)GFP Tag (1)
- Marqueur
Unconjugated (3)- (1)GFP Fusion (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT CC5-H52D1 |  Human | HEK293 | Human CCR5 Protein, Flag,His Tag (Detergent) |  |  |  |  Ajouter au panier |
HOT CC5-H52P3 | Human | HEK293 | Human CCR5 Full Length Protein (VLP) | | Ajouter au panier | ||
HOT CC5-M52D9 |  Mouse | HEK293 | Mouse CCR5 Protein, Flag,His Tag (Detergent) |  | | Ajouter au panier | |
CC5-H52P5 | Human | HEK293 | Fluorescent Human CCR5 Full Length Protein (VLP) | | Ajouter au panier | ||
CHEK-ATP043 | Human | HEK293 | HEK293/Human CCR5 Stable Cell Line |  | Ajouter au panier |
Quantité totale5
- 1
CCR5Alias de la molécule
CCR5,CMKBR5,CD195,CC-CKR-5,CHEMR13
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Takeda Pharmaceutical Co Ltd, Tobira Therapeutics Inc | AIDS Dementia Complex; Cholangitis, Sclerosing; Cognition Disorders; Coronavirus Disease 2019 (COVID-19); Diabetes Mellitus, Type 2; Hepatic Insufficiency; HIV Infections; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Prediabetic State | Details |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | Acquired Immunodeficiency Syndrome; Colorectal Neoplasms; HIV Infections | Details |
| Leronlimab | PA-14; PRO-140; HuPRO-140 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; HIV Infections; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Diabetic Nephropathies; Hyperplasia; Pancreatic Neoplasms | Details |
| RAP-103 | RAP-160; RAP-701; RAP-164; RAP-310; RAP-163; RAP-103 | Phase 2 Clinical | Rapid Pharmaceuticals | Alzheimer Disease; Hepatitis B; Neuralgia; Ovarian Neoplasms; Prostatic Neoplasms; Psoriasis | Details |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Amyotrophic Lateral Sclerosis; HIV Infections; Multiple Sclerosis | Details | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | Details |
| vMIP (Guangzhou Hongrun Biotech) | Phase 1 Clinical | Guangzhou Hongrun Biotechnology Co Ltd | Pneumonia | Details | |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Colorectal Neoplasms; Liver Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Solid tumours | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | Acquired Immunodeficiency Syndrome; Acute Lung Injury; AIDS Dementia Complex; Arthritis, Rheumatoid; Cardiovascular Diseases; Cognition Disorders; Coronavirus Disease 2019 (COVID-19); HIV Infections; Hypertriglyceridemia; Inflammation; Ischemic Stroke; Kidney Diseases; Primary Graft Dysfunction; Rejection of lung transplantation; Sarcoma, Kaposi; Stroke | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :